Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb 20;85(4):843-856.e6.
doi: 10.1016/j.molcel.2024.12.025. Epub 2025 Jan 24.

OXCT1 succinylation and activation by SUCLA2 promotes ketolysis and liver tumor growth

Affiliations

OXCT1 succinylation and activation by SUCLA2 promotes ketolysis and liver tumor growth

Dong Guo et al. Mol Cell. .

Abstract

Ketone bodies generated in hepatocytes in the adult liver are used for nonhepatic tissues as an energy source. However, ketolysis is reactivated in hepatocellular carcinoma (HCC) cells with largely unelucidated mechanisms. Here, we demonstrate that 3-oxoacid CoA-transferase 1 (OXCT1), a rate-limiting enzyme in ketolysis, interacts with SUCLA2 upon IGF1 stimulation in HCC cells. This interaction results from ERK2-mediated SUCLA2 S124 phosphorylation and subsequent PIN1-mediated cis-trans isomerization of SUCLA2. OXCT1-associated SUCLA2 generates succinyl-CoA, which not only serves as a substrate for OXCT1 but also directly succinylates OXCT1 at K421 and activates OXCT1. SUCLA2-regulated OXCT1 activation substantially enhances ketolysis, HCC cell proliferation, and tumor growth in mice. Notably, treatment with acetohydroxamic acid, an OXCT1 inhibitor used clinically for urinary infection, inhibits liver tumor growth in mice and significantly enhances lenvatinib therapy. Our findings highlight the role of SUCLA2-coupled regulation of OXCT1 succinylation in ketolysis and unveil an unprecedented strategy for treating HCC by interrupting ketolysis.

Keywords: OXCT1; SUCLA2; ketolysis; ketone body; succinyl-CoA; succinylation; tumorigenesis.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests Z. Lu owns shares in Signalway Biotechnology (Pearland, TX), which supplied the rabbit antibodies that recognize SUCLA2 pS124. Dr. Lu’s interest in this company had no bearing on it being chosen to supply these reagents.

Similar articles

Cited by

MeSH terms

LinkOut - more resources